Last updated: October 22, 2026
Xiaflex, the commercial collagenase clostridium histolyticum product, is a mature specialty biologic marketed by Endo. Its revenue base is concentrated in Dupuytren's contracture and Peyronie's disease, with commercial performance driven more by procedure volumes, physician adoption, reimbursement, and sales-force execution than by broad pharmaceutical demand.
U.S. sales have remained in the mid-$300 million range in recent years, but the product faces long-term erosion risks from surgical alternatives, needle aponeurotomy, physician treatment preferences, and potential follow-on biologic competition. Its regulatory exclusivity has expired, although the complexity of its collagenase mixture and limited market size have reduced immediate biosimilar pressure.
What is collagenase, and which drug is the commercial reference product?
The principal branded collagenase drug is Xiaflex, whose active ingredient is collagenase clostridium histolyticum, or CCH. It is an injectable biologic enzyme preparation derived from Clostridium histolyticum fermentation.
Xiaflex is approved in the United States for:
- Dupuytren's contracture in adults with a palpable cord
- Peyronie's disease in adult men with a palpable plaque and curvature deformity of at least 30 degrees at treatment initiation
The product received its first U.S. approval in 2010 for Dupuytren's contracture and expanded into Peyronie's disease in 2013. The FDA-approved product is administered by injection directly into diseased connective tissue, followed by a manipulation procedure in appropriate cases. The product is not a systemic treatment and has no broad primary-care market. [1]
What is the mechanism of action?
Xiaflex contains two collagenases that cleave collagen at multiple sites. In Dupuytren's contracture, the injected enzyme disrupts the collagen cord restricting finger extension. In Peyronie's disease, it targets collagen within the penile plaque.
The product's manufacturing and quality-control burden is higher than that of a conventional small-molecule generic. The active ingredient is a mixture of enzymes with structural, potency, impurity, and process attributes that must be controlled across fermentation, purification, formulation, and fill-finish operations.
How large is the collagenase drug market?
Xiaflex is the dominant commercial collagenase drug in its approved U.S. indications. The market is smaller than markets for autoimmune biologics, oncology drugs, or diabetes therapies because treatment is procedure-based and limited to specific patient populations.
The market has four structural characteristics:
- Demand is linked to diagnosis and referral rates.
- Revenue depends on physician procedure frequency rather than chronic prescription volume.
- Reimbursement and site-of-care economics influence use.
- Treatment competes with procedures that do not require drug acquisition.
Dupuytren's contracture provides the broader patient pool, but Peyronie's disease has helped diversify Xiaflex revenue and increased average commercial value per treated patient. Both indications require specialist diagnosis, patient selection, and procedural expertise.
What drives demand for Xiaflex?
The main growth drivers are:
- Greater diagnosis of Dupuytren's contracture and Peyronie's disease
- Increased use by urologists, hand surgeons, and orthopedic specialists
- Expansion of physicians trained to administer the product
- Reimbursement coverage for injection and post-injection manipulation
- Preference for minimally invasive treatment in selected patients
- Repeat treatment in eligible patients, subject to label limitations
The principal restraints are the need for a procedure-trained specialist, adverse-event concerns, patient willingness to undergo injection, and the availability of surgery or needle aponeurotomy.
What is the financial trajectory of Xiaflex?
Endo's public filings have placed Xiaflex in the company's branded pharmaceutical portfolio. Reported annual sales have generally remained around the mid-$300 million level rather than following a high-growth biologic trajectory.
| Period |
Commercial position |
Financial interpretation |
| 2010 |
FDA approval for Dupuytren's contracture |
Initial specialty-market launch |
| 2013 |
FDA approval for Peyronie's disease |
Expansion into urology and increased addressable demand |
| 2015 |
Endo acquired Auxilium Pharmaceuticals |
Endo obtained the commercial platform for Xiaflex |
| 2021 |
Endo acquired BioSpecifics Technologies |
Endo consolidated additional Xiaflex-related rights and economics |
| 2022-2023 |
Mature branded-product period |
Annual sales remained approximately in the mid-$300 million range |
| 2024 onward |
Post-bankruptcy Endo ownership |
Product cash flow remains important to a financially restructured company |
Endo's reported Xiaflex revenue has been approximately $350 million annually in the most recent reporting period before Endo's private-company restructuring. Exact period comparisons depend on foreign-exchange treatment, portfolio classification, and whether reported figures include related product economics. [2][3]
Why has Xiaflex revenue not grown like a typical biologic?
Xiaflex has limited indication breadth and a finite procedural market. The drug also depends on treatment capacity. A pharmaceutical company can increase chronic-use prescriptions through broad primary-care adoption, but Xiaflex requires:
- A confirmed anatomical condition
- Specialist evaluation
- Injection capability
- Post-injection monitoring or manipulation
- Reimbursement approval
- Patient acceptance of a procedure
Revenue growth has therefore been constrained by clinical workflow and physician capacity. The product is commercially valuable because of its pricing and specialist positioning, but its sales ceiling is lower than that of a chronic-use biologic with multiple systemic indications.
What companies own and commercialize collagenase?
Endo is the principal current commercial owner of Xiaflex in the United States. The product originated through Auxilium Pharmaceuticals, which Endo acquired in 2015. BioSpecifics Technologies was associated with the development and intellectual-property history of Xiaflex and was acquired by Endo in 2021 for approximately $658 million. [3][4]
| Company |
Role |
| Endo |
Current commercial owner and marketer of Xiaflex |
| Auxilium Pharmaceuticals |
Former commercial owner before Endo's acquisition |
| BioSpecifics Technologies |
Former collagenase developer and rights holder |
| Pfizer |
Historical development and licensing participant associated with the collagenase program |
Endo's ownership of the commercial and development rights increases strategic control over pricing, manufacturing, regulatory activities, and lifecycle management. It also concentrates product risk within a company that has undergone significant financial restructuring.
What is the FDA regulatory status of Xiaflex?
Xiaflex is an FDA-approved biologic licensed under Biologics License Application No. 125338. Its approved indications are Dupuytren's contracture and Peyronie's disease. [1]
The product's 12-year U.S. reference-product exclusivity period has expired. The original 2010 approval means that statutory biologic data exclusivity would have ended in 2022, subject to the applicable regulatory calculation. Expiration of data exclusivity does not automatically create a competing product. A follow-on applicant would still need to establish biosimilarity or interchangeability and address manufacturing, analytical, clinical, and patent issues.
Is Xiaflex listed in the Orange Book?
Xiaflex is a biologic licensed under the Public Health Service Act rather than a conventional small-molecule drug approved through a standard NDA. Its regulatory reference framework is therefore the Purple Book and the Biologics Price Competition and Innovation Act, or BPCIA, rather than the conventional Orange Book and Hatch-Waxman pathway. [5][6]
This distinction affects the likely litigation route:
- A biosimilar applicant would generally use the BPCIA process.
- Patent disputes would not necessarily follow the standard Paragraph IV framework.
- The absence of an Orange Book-style listing does not eliminate patent-based launch risk.
- Product-specific regulatory exclusivity and patent protection must be analyzed separately.
What patents protect Xiaflex and collagenase clostridium histolyticum?
Xiaflex has historically been protected by patents covering collagenase compositions, production methods, formulation, dosing, and therapeutic use. The relevant protection is layered rather than dependent on one molecule patent because CCH is a biologic enzyme mixture.
The key patent categories are:
| Patent category |
Commercial relevance |
| Composition patents |
Protect collagenase preparations or defined enzyme combinations |
| Manufacturing patents |
Cover fermentation, purification, activity control, and process conditions |
| Formulation patents |
Address stability, excipients, concentration, and storage |
| Method-of-use patents |
Cover treatment of Dupuytren's contracture or Peyronie's disease |
| Dosing and administration patents |
Protect injection schedules, manipulation protocols, and treatment sequencing |
Patent strength is mixed. Composition and manufacturing claims can create meaningful technical barriers if they cover the commercial product and are difficult to design around. Method-of-use claims may be narrower because a biosimilar or competing product can seek a label that omits patented indications, subject to applicable regulatory rules.
Publicly available patent records should be reviewed claim-by-claim because the effective protection period differs by patent, terminal disclaimer, patent-term adjustment, and any applicable pediatric extension. The 12-year biologic exclusivity period has ended, but patent expiry may extend beyond regulatory exclusivity for particular uses or processes.
Are there Paragraph IV challenges or biosimilar competitors?
No widely commercialized U.S. biosimilar or generic equivalent to Xiaflex had materially disrupted the market through mid-2024. The absence of a competitor reflects several barriers:
- CCH is a complex enzyme mixture rather than a simple defined small molecule.
- Analytical similarity is more demanding than for conventional generics.
- Manufacturing consistency is difficult to demonstrate.
- The commercial opportunity is moderate relative to the cost of developing a complex biologic.
- Specialist administration and reimbursement reduce the value of a simple price-discount strategy.
- Patent and regulatory strategies can delay or narrow market entry.
A future follow-on entrant could pursue a biosimilar BLA, but substitution would not be automatic. Interchangeability, physician familiarity, payer policy, device or presentation differences, and indication-specific labeling would affect uptake.
What generic launch risks exist?
The most credible launch scenarios are:
- A biosimilar enters after resolving composition, manufacturing, and use patents.
- A follow-on product launches with a limited label that excludes patented indications.
- A competitor enters through a different collagenase preparation or administration method.
- Existing procedural alternatives gain share without a direct drug competitor.
The first commercial entrant would face a specialized market with meaningful education and contracting costs. A low-price product could gain share with payers, but physician adoption would depend on potency consistency, safety data, supply reliability, and reimbursement treatment.
What competitive products challenge Xiaflex?
Xiaflex competes primarily against procedures, not against another approved collagenase drug.
Dupuytren's contracture competitors
- Open fasciectomy
- Needle aponeurotomy or needle fasciotomy
- Observation for less severe disease
- Physical therapy and postoperative rehabilitation
Surgery may provide durable correction but carries greater procedural burden and recovery requirements. Needle aponeurotomy can be less invasive and less expensive in selected cases. Xiaflex occupies an intermediate position between observation and surgery, particularly for patients with a palpable cord and suitable anatomy.
Peyronie's disease competitors
- Intralesional verapamil or other off-label injections
- Penile traction therapy
- Oral or symptomatic treatments
- Plaque incision, grafting, or penile prosthesis surgery
- Observation in stable or less disabling disease
Xiaflex benefits from its FDA-approved indication, but its use depends on disease characteristics, curvature severity, erectile function, patient preference, and urologist experience.
What litigation and settlement issues affect collagenase?
The principal legal risks are expected to involve:
- Patent validity and infringement
- Biosimilar patent-dance disputes
- Manufacturing-process claims
- Labeling and induced-infringement theories
- Reimbursement and product-liability claims
- Contract disputes involving development or commercialization rights
No major public U.S. Paragraph IV settlement involving a commercially launched Xiaflex generic had materially changed the market through mid-2024. Any future settlement could establish a negotiated launch date, license terms, manufacturing restrictions, or royalty obligations.
Endo's bankruptcy and restructuring add a separate commercial-law dimension. Intellectual-property ownership, licensing rights, royalty streams, and obligations connected with Xiaflex must be evaluated against the company's restructuring documents and asset-transfer arrangements. [7]
How strong is the collagenase patent estate?
The estate is stronger as a combined regulatory, manufacturing, and clinical-use package than as a single composition monopoly.
| Factor |
Assessment |
| Regulatory exclusivity |
Expired for the original 2010 biologic approval |
| Product complexity |
High; favors the incumbent against simple replication |
| Manufacturing barrier |
High relative to small-molecule generics |
| Method-of-use protection |
Potentially meaningful but indication-specific |
| Formulation protection |
Relevant if claims read on commercial stability and presentation |
| Biosimilar risk |
Low in the near term, rising as development economics improve |
| Procedure competition |
Persistent and clinically significant |
| Revenue durability |
Moderate, supported by specialist demand but limited by market size |
The patent estate should not be treated as a permanent barrier. A biosimilar may avoid selected method-of-use claims, while process claims can be challenged or designed around. The more durable defenses are likely to be manufacturing know-how, clinical experience, physician training, supply reliability, and payer relationships.
What is the commercial outlook for Xiaflex?
Xiaflex is likely to remain a cash-generating specialty biologic rather than a high-growth platform product. The most probable trajectory is stable-to-declining revenue, with performance determined by indication mix and procedural utilization.
Upside could come from:
- Greater Peyronie's disease diagnosis
- Increased specialist training
- Better payer coverage
- Expanded use in suitable Dupuytren's patients
- International commercialization or licensing
Downside could come from:
- Surgical and needle-based alternatives
- Reimbursement reductions
- Safety concerns involving tendon rupture, skin injury, or hematoma
- Physician migration to lower-cost procedures
- Biosimilar entry
- Endo supply or commercial execution problems
For investors and licensing counterparties, the central question is not whether collagenase has a clinical market. It does. The question is whether Endo can preserve price, physician preference, and procedural volume after biologic exclusivity expiry.
Key Takeaways
- Xiaflex is the principal commercial collagenase clostridium histolyticum drug.
- Endo owns and commercializes the product after acquiring Auxilium and BioSpecifics-related assets.
- U.S. sales have been approximately in the mid-$300 million range in recent reporting periods.
- FDA approval covers Dupuytren's contracture and Peyronie's disease.
- The original 12-year biologic exclusivity period expired in 2022.
- Xiaflex is governed primarily by the biologic and BPCIA framework rather than a conventional Orange Book Paragraph IV pathway.
- No major biosimilar had materially disrupted the U.S. market through mid-2024.
- Manufacturing complexity and specialist administration delay competitive entry.
- Surgery and needle aponeurotomy are more important current competitors than another collagenase drug.
- Revenue durability is moderate, with long-term erosion risk from procedure substitution and future biosimilar competition.
FAQs About Collagenase Drug Market Dynamics
Is Xiaflex a biologic or a generic drug?
Xiaflex is a biologic enzyme product licensed under a BLA. It is not a conventional small-molecule generic.
What diseases does collagenase treat?
FDA-approved Xiaflex treats Dupuytren's contracture and Peyronie's disease in defined adult patient populations.
Does Xiaflex have a biosimilar?
No widely commercialized U.S. biosimilar had materially entered the market through mid-2024.
Who manufactures collagenase clostridium histolyticum?
Endo is the commercial owner of Xiaflex. Manufacturing arrangements may involve specialized third-party facilities and must be reviewed through current regulatory and corporate filings.
Is collagenase a high-growth pharmaceutical market?
No. The market is a focused specialty-procedure market with meaningful revenue but limited indication breadth and persistent competition from surgery and other interventions.
References
- U.S. Food and Drug Administration. (2024). Xiaflex prescribing information. https://www.accessdata.fda.gov
- Endo International plc. (2024). Annual report and financial filings. https://www.endo.com
- Endo International plc. (2021). Endo completes acquisition of BioSpecifics Technologies. https://www.endo.com
- Endo International plc. (2015). Endo completes acquisition of Auxilium Pharmaceuticals. https://www.endo.com
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
- United States Bankruptcy Court for the Southern District of Texas. (2023-2024). In re Endo International plc, Chapter 11 restructuring proceedings. https://cases.ra.kroll.com/EndoInternational